Related references
Note: Only part of the references are listed.Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection
Eric J. Lawitz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6
Juan Angel Patino-Galindo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Analysis of hepatitis C NS5A resistance associated polymorphisms using ultra deep single molecule real time (SMRT) sequencing
Assar Bergfors et al.
ANTIVIRAL RESEARCH (2016)
Hepatitis C virus whole genome sequencing: Current methods/issues and future challenges
Pauline Tremeaux et al.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2016)
Prevention and management of treatment failure to new oral hepatitis C drugs
Laura Benitez-Gutierrez et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens
Jean-Michel Pawlotsky
GASTROENTEROLOGY (2016)
Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in Hepatitis C Virus Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study
Paul Kwo et al.
HEPATOLOGY (2016)
Simeprevir Plus Sofosbuvir in Patients With Chronic Hepatitis C Virus Genotype 1 Infection and Cirrhosis: A Phase 3 Study (OPTIMIST-2)
Eric Lawitz et al.
HEPATOLOGY (2016)
Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection
Jun Ito et al.
HEPATOLOGY RESEARCH (2016)
Clinical relevance of the HCV protease inhibitor-resistant mutant viral load assessed by ultra-deep pyrosequencing in treatment failure
Sofiane Mohamed et al.
JOURNAL OF CLINICAL VIROLOGY (2016)
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
Christoph Sarrazin
JOURNAL OF HEPATOLOGY (2016)
Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives
Tarik Asselah et al.
LIVER INTERNATIONAL (2016)
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection A Randomized Trial
Stefan Zeuzem et al.
ANNALS OF INTERNAL MEDICINE (2015)
Evolution of Hepatitis C Virus Quasispecies during Repeated Treatment with the NS3/4A Protease Inhibitor Telaprevir
Simone Susser et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir
Preethi Krishnan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
Raymond T. Chung et al.
HEPATOLOGY (2015)
Development and persistence of DAA resistance associated mutations in patients failing HCV treatment
Stefania Paolucci et al.
JOURNAL OF CLINICAL VIROLOGY (2015)
LONG-TERM PERSISTENCE OF HCV NS5A VARIANTS AFTER TREATMENT WITH NS5A INHIBITOR LEDIPASVIR
H. Dvory-Sobol et al.
JOURNAL OF HEPATOLOGY (2015)
LONG-TERM FOLLOW-UP OF TREATMENT-EMERGENT RESISTANCE-ASSOCIATED VARIANTS IN NS3, NS5A AND NS5B WITH PARITAPREVIR/R-, OMBITASVIR- AND DASABUVIR-BASED REGIMENS
P. Krishnan et al.
JOURNAL OF HEPATOLOGY (2015)
Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies
Oliver Lenz et al.
JOURNAL OF HEPATOLOGY (2015)
RETREATMENT OF PATIENTS WHO FAILED 8 OR 12 WEEKS OF LEDIPASVIR/SOFOSBUVIR- BASED REGIMENS WITH LEDIPASVIR/SOFOSBUVIR FOR 24 WEEKS
E. Lawitz et al.
JOURNAL OF HEPATOLOGY (2015)
EASL Recommendations on Treatment of Hepatitis C 2015
JOURNAL OF HEPATOLOGY (2015)
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent
Xavier Forns et al.
JOURNAL OF HEPATOLOGY (2015)
Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy
Satoshi Yoshimi et al.
JOURNAL OF MEDICAL VIROLOGY (2015)
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
Mark Sulkowski et al.
LANCET (2015)
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
G. R. Foster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
J. J. Feld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients
Julia Dietz et al.
PLOS ONE (2015)
Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance
Lize Cuypers et al.
VIRUSES-BASEL (2015)
Virologic Tools for HCV Drug Resistance Testing
Slim Fourati et al.
VIRUSES-BASEL (2015)
In Vitro and In Vivo Antiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5A
Preethi Krishnan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
In Vitro and In Vivo Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450
Tami Pilot-Matias et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
In Vitro Activity and Resistance Profile of Dasabuvir, a Nonnucleoside Hepatitis C Virus Polymerase Inhibitor
Warren Kati et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Clinical Evidence and Bioinformatics Characterization of Potential Hepatitis C Virus Resistance Pathways for Sofosbuvir
Eric F. Donaldson et al.
HEPATOLOGY (2015)
Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1
K. Kosaka et al.
JOURNAL OF VIRAL HEPATITIS (2015)
Comparison of Daclatasvir Resistance Barriers on NS5A from Hepatitis C Virus Genotypes 1 to 6: Implications for Cross-Genotype Activity
Chunfu Wang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Hepatitis C Virus Genetic Variability and the Presence of NS5B Resistance- Associated Mutations as Natural Polymorphisms in Selected Genotypes Could Affect the Response to NS5B Inhibitors
V. C. Di Maio et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region
William L. Irving et al.
ANTIVIRAL RESEARCH (2014)
Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?
Maximilian David Schneider et al.
ANTIVIRAL RESEARCH (2014)
Infrequent Development of Resistance in Genotype 1-6 Hepatitis C Virus-Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials
Evguenia S. Svarovskaia et al.
CLINICAL INFECTIOUS DISEASES (2014)
Detection of a Sexually Transmitted Hepatitis C Virus Protease Inhibitor-Resistance Variant in a Human Immunodeficiency Virus-Infected Homosexual Man
Sandra Franco et al.
GASTROENTEROLOGY (2014)
Expanded Classification of Hepatitis C Virus Into 7 Genotypes and 67 Subtypes: Updated Criteria and Genotype Assignment Web Resource
Donald B. Smith et al.
HEPATOLOGY (2014)
Poster Session 4: Hepatitis C: New Agents (Not Approved)
HEPATOLOGY (2014)
Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection
Hiromitsu Kumada et al.
HEPATOLOGY (2014)
Global epidemiology and genotype distribution of the hepatitis C virus infection
Erin Gower et al.
JOURNAL OF HEPATOLOGY (2014)
Protease Inhibitor Resistance Mutations in Untreated Brazilian Patients Infected with HCV: Novel Insights about Targeted Genotyping Approaches
Isabel M. V. G. de Carvalho et al.
JOURNAL OF MEDICAL VIROLOGY (2014)
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
Michael Manns et al.
LANCET (2014)
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
Eric Lawitz et al.
LANCET (2014)
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
Ira M. Jacobson et al.
LANCET (2014)
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
Michael Manns et al.
LANCET (2014)
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
Eric Lawitz et al.
LANCET (2014)
HCV direct-acting antiviral agents: the best interferon-free combinations
Raymond Schinazi et al.
LIVER INTERNATIONAL (2014)
Retreatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin
Jordan J. Feld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Mark S. Sulkowski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
New Hepatitis C Virus (HCV) Drugs and the Hope for a Cure: Concepts in Anti-HCV Drug Development
Jean-Michel Pawlotsky
SEMINARS IN LIVER DISEASE (2014)
Hepatitis C drugs: The end of the pegylated interferon era and the emergence of all-oral, interferon-free antiviral regimens: A concise review
Alan Hoi Lun Yau et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2014)
Low-Level Persistence of Drug Resistance Mutations in Hepatitis B Virus-Infected Subjects with a Past History of Lamivudine Treatment
Severine Margeridon-Thermet et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885
Kelly A. Wong et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics
Eric Lawitz et al.
ANTIVIRAL RESEARCH (2013)
Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials
James C. Sullivan et al.
CLINICAL INFECTIOUS DISEASES (2013)
Hepatitis C therapy with HCV NS5B polymerase inhibitors
Vincent Soriano et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Resistance Analysis of Hepatitis C Virus Genotype 1 Prior Treatment Null Responders Receiving Daclatasvir and Asunaprevir
Fiona McPhee et al.
HEPATOLOGY (2013)
Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics A Randomized Clinical Trial
Anuoluwapo Osinusi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
JOURNAL OF HEPATOLOGY (2013)
Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment
Doug J. Bartels et al.
JOURNAL OF VIROLOGY (2013)
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
Edward J. Gane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: A population and clonal analysis
Richard J. O. Barnard et al.
VIROLOGY (2013)
Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies
Richard J. O. Barnard et al.
VIROLOGY (2013)
Resistance Analysis of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir
Fiona McPhee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor
Zulema Plaza et al.
ANTIVIRAL THERAPY (2012)
New Virologic Tools for Management of Chronic Hepatitis B and C
Stephane Chevaliez et al.
GASTROENTEROLOGY (2012)
Efficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virus-Infected Patients Following TMC435 Monotherapy
Oliver Lenz et al.
GASTROENTEROLOGY (2012)
Antiviral strategies in hepatitis C virus infection
Christoph Sarrazin et al.
JOURNAL OF HEPATOLOGY (2012)
ANTIVIRAL ACTIVITY AND RESISTANCE PROFILE OF THE NOVEL HCV NS5A INHIBITOR GS-5885
G. Cheng et al.
JOURNAL OF HEPATOLOGY (2012)
Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b
J. Vermehren et al.
JOURNAL OF VIRAL HEPATITIS (2012)
Analysis of Hepatitis C Virus Intrahost Diversity across the Coding Region by Ultradeep Pyrosequencing
Michael Lauck et al.
JOURNAL OF VIROLOGY (2012)
Viral Quasispecies Evolution
Esteban Domingo et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2012)
Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients
Stefania Paolucci et al.
VIROLOGY JOURNAL (2012)
Treatment Failure and Resistance with Direct-Acting Antiviral Drugs Against Hepatitis C Virus
Jean-Michel Pawlotsky
HEPATOLOGY (2011)
Genotypic and Phenotypic Analysis of Variants Resistant to Hepatitis C Virus Nonstructural Protein 5A Replication Complex Inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations
Robert A. Fridell et al.
HEPATOLOGY (2011)
Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir
Simone Susser et al.
JOURNAL OF CLINICAL VIROLOGY (2011)
Genetic Heterogeneity of Hepatitis C Virus in Association with Antiviral Therapy Determined by Ultra-Deep Sequencing
Akihiro Nasu et al.
PLOS ONE (2011)
In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435
Oliver Lenz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)
Tara L. Kieffer et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
Libin Rong et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
HCV variability, the immune system and resistance to antiviral drugs
Jean-Michel Pawlotsky
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2009)
Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?
Vincent Soriano et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients
Sophie Le Pogam et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3•4A protease inhibitors in treatment-naive subjects
Doug J. Bartels et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir
Christoph Sarrazin et al.
GASTROENTEROLOGY (2007)
Share Paper
